MDM2 and renal cell carcinoma: To investigate the effects of TGase 2 and MDM2 on p53 protein levels in RCC, we targeted them using streptonigrin (which inhibits TGase 2-p53 binding) [15] and nutlin-3a (which inhibits MDM2-p53 binding) [7] (Figure 2A, Figure S2).